Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Subtle brain abnormalities in adrenomyeloneuropathy].

C Teriitehau1, C Adamsbaum, V Merzoug

  • 1Service de Radiologie. H.I.A. Percy, boulevard Henry Barbusse, 92 Clamart, France - 16 rue des Réservoirs, 78000 Versailles, France. cterii@caramail.com

Journal De Radiologie
|September 20, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Secondary progressive multiple sclerosis: A national consensus paper on diagnostic criteria.

Revue neurologique·2022
Same author

Periventricular hemorrhagic infarction (PVHI) associated with intraventricular hemorrhage (IVH) in premature infants: Outcome at 2 years of age.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2022
Same author

Health related quality of life and perceived social support in French and Lebanese MS patients: A comparative study.

Multiple sclerosis and related disorders·2022
Same author

E.U. paediatric MOG consortium consensus: Part 4 - Outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2020
Same author

E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2020
Same author

Radiofrequency ablation versus surgical resection for the treatment of oligometastatic lung disease.

Diagnostic and interventional imaging·2020
Same journal

[Not Available].

Journal de radiologie·2014
Same journal

[Not Available].

Journal de radiologie·2014
Same journal

[Not Available].

Journal de radiologie·2014
Same journal

[Not Available].

Journal de radiologie·2014
Same journal

[Not Available].

Journal de radiologie·2014
Same journal

[Not Available].

Journal de radiologie·2014
See all related articles

Subtle MRI abnormalities, including corticospinal tract signal changes and white matter pallor, are common in adrenomyeloneuropathy (AMN) patients without overt brain lesions. These findings help define the MRI pattern of AMN.

Area of Science:

  • Neurology
  • Radiology
  • Genetics

Context:

  • Adrenomyeloneuropathy (AMN) is an X-linked neurodegenerative disorder.
  • Brain involvement in AMN can be subtle and difficult to detect.
  • Early MRI detection of brain abnormalities is crucial for prognosis.

Purpose:

  • To characterize subtle MRI findings in adult AMN patients without apparent brain lesions.
  • To identify specific patterns of white matter and tract abnormalities on MRI.
  • To establish a semi-quantitative scale for evaluating these subtle changes.

Summary:

  • Retrospective analysis of 66 adult AMN patients revealed abnormalities in 54.6% involving corticospinal tracts.
  • Additional subtle findings included parieto-occipital white matter pallor and patchy hyperintensity.

Related Experiment Videos

  • Hyperintense pontocerebellar fibers were observed in 41.7% of patients, confirming literature findings on elevated metabolites.

    • Impact:

    • This study provides a detailed description of the MRI pattern in AMN patients lacking significant white matter or callosal abnormalities.
    • The findings aid in the early diagnosis and monitoring of neurological progression in AMN.
    • Establishes a baseline for future therapeutic trials targeting brain involvement in AMN.